Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
MWN-AI** Summary
Trevi Therapeutics, Inc. has announced the appointment of David Hastings as the new Chief Financial Officer (CFO), effective January 6, 2026. Trevi, a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, sees this move as pivotal to its financial strategy and future growth.
Hastings brings over 25 years of financial leadership experience in the life sciences and biopharmaceutical sectors, having raised more than $2 billion in equity and debt financing throughout his career. His previous roles include CFO at Arbutus, Senior Vice President at Unilife, and CFO at Incyte, where he played a significant role in the company's transition to commercialization following the launch of the drug Jakafi®. His expertise in commercializing biopharmaceutical products will be beneficial as Trevi prepares for Phase 3 development of Haduvio.
Jennifer Good, President and CEO of Trevi Therapeutics, expressed enthusiasm about Hastings' appointment, emphasizing the importance of his proven expertise during this crucial phase of development. Hastings himself shared his excitement about joining Trevi’s mission, highlighting the significant potential for Haduvio to fulfill an unmet medical need for chronic cough patients.
Chronic cough is a debilitating condition affecting many patients with IPF and non-IPF ILD where no FDA-approved therapies currently exist. Trevi's investigation into Haduvio aims to address this substantial market gap.
For more information about Trevi Therapeutics and its developments, visit their website or follow them on social media platforms.
MWN-AI** Analysis
The recent appointment of David Hastings as Chief Financial Officer at Trevi Therapeutics (Nasdaq: TRVI) is a notable strategic maneuver that merits attention from investors and analysts alike. His extensive experience in the biotechnology sector, particularly his proven track record of capital raising and financial management, is likely to bolster Trevi’s financial strategies as it approaches key milestones in the development of Haduvio™—an investigational therapy targeting chronic coughs linked to chronic lung diseases.
Hastings’ role is pivotal as Trevi transitions into Phase 3 development, a stage crucial for regulatory approval and commercialization. His prior success in raising over $2 billion in equity and debt financing will be instrumental for Trevi, especially given the financial demands associated with advancing clinical trials and preparing for market entry. The fiscal stability he can bring will instill confidence in both investors and existing stakeholders.
Trevi’s focus on treating chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease highlights a significant market opportunity, as these conditions present a high unmet need. With approximately 150,000 patients in the U.S. with IPF alone and limited competitive products in this niche, Haduvio™ could capture substantial market share.
For investors, this is a prime time to monitor Trevi Therapeutics closely. The combination of Hastings' financial leadership and Trevi's innovative product pipeline positions the company well for potential upside. However, it's crucial to recognize inherent risks associated with drug development, including regulatory hurdles and market entry challenges. As such, investors should weigh the prospects of Trevi’s growth against these risks while considering a diversified investment strategy to mitigate exposure. In summary, Trevi Therapeutics appears poised for an important growth phase, making it a stock to watch closely in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.
Mr. Hastings brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies to Trevi. His accomplishments span capital raising, commercialization, business development, and investor relations management. Throughout his career, Mr. Hastings has raised over $2B in equity and debt financing. Most recently, Mr. Hastings was Chief Financial Officer (CFO) at Arbutus from June 2018 until March 2025. Previously, he was Senior Vice President and CFO of Unilife from 2015 until 2017. Prior to that, he spent the majority of his career as CFO and Executive Vice President at Incyte, a role he held from 2003 to 2014. During his tenure at Incyte, Mr. Hastings oversaw all financial aspects of the company's transition from research and development to commercialization following the launch of Jakafi® (ruxolitinib). He was integral in managing the financial and operational complexities of scaling the company to over 700 individuals. Additionally, he co-led the negotiation of two out-licensing deals for two compounds. Mr. Hastings also previously served as Vice President, CFO and Treasurer at ArQule Inc., where he played an important role in the company's transition into a drug discovery and development organization, and in its two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Currently, Mr. Hastings is a Board member and Chair of the Audit Committee of Scynexis, Inc.
"I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi," said Jennifer Good, President and CEO of Trevi Therapeutics. "His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough."
"I am happy to join Trevi as they continue to pioneer a potential treatment option for patients with chronic cough," said David Hastings. "Trevi is at an exciting stage of development with statistically significant data across target indications, limited competition, and a strong cash position. I look forward to leveraging my experience to accelerate its path to long-term value for both patients and shareholders."
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8?weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans with respect to clinical trials, expectations regarding Trevi's sufficiency of capital, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations, including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact?
Jonathan Carlson?
Trevi Therapeutics, Inc.?
(203) 654 3286?
carlsonj@trevitherapeutics.com?
Media Contact?
Rosalia Scampoli?
914-815-1465?
rscampoli@marketcompr.com
SOURCE Trevi Therapeutics, Inc.
FAQ**
How will David Hastings' extensive experience in capital raising and commercialization benefit Trevi Therapeutics Inc. (TRVI) as it transitions into Phase 3 development for Haduvio?
What specific strategies does Trevi Therapeutics Inc. (TRVI) plan to implement under David Hastings' leadership to maintain its strong cash position during upcoming clinical trials?
Given the high unmet need for chronic cough treatments, how does Trevi Therapeutics Inc. (TRVI) plan to leverage Haduvio's statistically significant clinical trial data to attract potential investors?
What role will David Hastings play in enhancing investor relations at Trevi Therapeutics Inc. (TRVI), especially in communicating the company's financial strategies and clinical development progress?
**MWN-AI FAQ is based on asking OpenAI questions about Trevi Therapeutics Inc. (NASDAQ: TRVI).
NASDAQ: TRVI
TRVI Trading
-3.09% G/L:
$11.61 Last:
920,560 Volume:
$11.70 Open:
